Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28394362 | 0.84 | IDO1 (0.44) | IDO1TAAR1KMT2AMEN1NPC1 | |
| SCHEMBL28948497 | 0.84 | SMN1; SMN2 (0.47) | IDO1TAAR1KMT2AMEN1NPC1 | |
| SCHEMBL4460773 | 0.83 | HIF1A (0.49) | TAAR1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL7280783 | 0.82 | CYP2C9 (0.53) | BLMIDO1KMT2AMEN1HPGD | |
| SCHEMBL7280790 | 0.82 | CYP2C9 (0.53) | BLMIDO1KMT2AMEN1HPGD | |
| SCHEMBL8873840 | 0.81 | BCHE (0.55) | KMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL8873833 | 0.81 | BCHE (0.55) | KMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL8873826 | 0.81 | BCHE (0.55) | KMT2AMEN1LMNAL3MBTL1 | |
| SCHEMBL12266005 | 0.81 | MEN1 (0.46) | TAAR1KMT2AMEN1NPC1RAB9A | |
| SCHEMBL6718555 | 0.80 | HSD17B10 (0.59) | IDO1TAAR1KMT2AMEN1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993800-B2 | Process for producing optically active α-methylcysteine derivative | KANEKA CORPORATION (JP) | 2015-03-31 | — | — | US | disclosed |
| EP-2287152-B1 | Process for producing optically active alpha-methylcysteine derivative | KANEKA CORP (JP) | 2015-01-14 | — | — | EP | disclosed |
| US-20130261331-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-METHYLCYSTEINE DERIVATIVE | KANEKA CORP (JP) | 2013-10-03 | — | — | US | disclosed |
| EP-2287152-A2 | Process for producing optically active alpha-methylcysteine derivative | KANEKA CORPORATION (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20100197934-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2010-08-05 | — | — | US | disclosed |
| US-20060105435-A1 | Process for producing optically active alpha-methylcysteine derivative | KANEKA CORPORATION (JP) | 2006-05-18 | — | — | US | disclosed |
| EP-1550725-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE | KANEKA CORPORATION (JP) | 2005-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197934-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE ALPHA-METHYLCYSTEINE DERIVATIVE | AHCY, CTH, BHMT | BLM 4277/4885IDO1 1209/4885TAAR1 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.